Smith+Nephew opens new state-of-the-art surgical innovation and training centre in the heart of Munich
LONDON, Oct. 11, 2023 /PRNewswire/ — Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company specialising in orthopaedics, advanced wound management and sports medicine, is pleased to announce the opening of the purpose-built Smith+Nephew Academy Munich, a new centre for surgical innovation and training.
S+N Academy Munich, situated in Kustermann Park in the heart of the city, will provide a central European hub for surgeons from across Europe, the Middle East and Africa. Surgeons and other healthcare specialists will learn the latest surgical techniques using the most advanced technology available, and practice surgical techniques using both hands-on and fully immersive digital interactive experiences.
S+N Academy Munich is the latest addition to a global network of nine Academies, across three continents. At its peak, S+N Academy Munich is expected to train up to 5,000 global healthcare providers at the site each year.
Additionally, S+N Academy Munich will also serve as a hub to connect healthcare professionals with its global marketing and research and development teams to test and validate new technologies.
‘Our investment in S+N Academy Munich is part of a global commitment to drive innovation and learning in medical technology, creating an environment where the best healthcare providers can learn, collaborate, and innovate in order to meet the needs of their patients,’ said Cynthia Walker, Global Senior Vice President for Medical Education, Smith+Nephew.
The ageing population, particularly in industrialised countries, has led to a growing demand for new technology and digital solutions to both improve outcomes and meet the cost-efficiencies demanded by value-oriented healthcare systems. Smith+Nephew is committed to ongoing investment in research and development to further our purpose of ensuring patients can live their Life Unlimited. The new S+N Academy Munich is another major investment in the training and education of healthcare professionals.
‘In 2023, we launched more than 20 new products in orthopaedics, sports medicine and wound care. The evolution of new technologies is allowing us to constantly realise, develop and implement what’s possible in healthcare, improving outcomes for patients and meeting the demands of health systems worldwide,’ said Kenneth Garcia, Senior Vice President & General Manager for Orthopaedics International, Smith+Nephew.
Smith+Nephew is a portfolio medical technology company focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 19,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.2 billion in 2022. Smith+Nephew is a constituent of the FTSE100 (LSE: SN, NYSE: SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of Covid, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of Covid; economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers (including, without limitation, as a result of Covid); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of Covid); competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew’s most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew’s expectations.
™Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.
Photo – https://mma.prnewswire.com/media/2243724/Munich_Office_20.jpg
Logo – https://mma.prnewswire.com/media/3924/Smith_Nephew_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/smithnephew-opens-new-state-of-the-art-surgical-innovation-and-training-centre-in-the-heart-of-munich-301953090.html
Disclaimer: The above press release comes to you under an arrangement with PR Newswire. Millionaireoutlook.com takes no editorial responsibility for the same.